Draconis Pharma

Draconis Pharma is a biotechnology company dedicated to developing next-generation small molecule inhibitors for the treatment of cancer. The company's research centers on the deubiquitylating enzyme (DUB) space, specifically targeting Ubiquitin Specific Peptidase 7 (USP7) to modulate protein degradation pathways. By inhibiting USP7, Draconis seeks to restore the function of key tumor suppressor proteins, such as p53, which are often downregulated in cancer cells. Based in the United Kingdom, the firm utilizes a structure-based drug design approach to create highly selective and potent therapeutic candidates. The company operates within the Stevenage Bioscience Catalyst, benefiting from a collaborative environment focused on life science innovation. Draconis Pharma aims to address unmet needs in oncology by leveraging its expertise in the ubiquitin-proteasome system.